Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssens AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1). The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $1.36375 billion
- Outstanding Shares: 94,432,000
Average Prices:- 50 Day Moving Avg: $11.70
- 200 Day Moving Avg: $11.70
- 52 Week Range: $10.44 - $22.70
P/E:- Trailing P/E Ratio: 263.23
- Foreward P/E Ratio: 12.24
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $236.21 million
- Price / Sales: 5.68
- Book Value: $3.63 per share
- Price / Book: 3.91
Profitability:- EBIDTA: $61.58 million
- Net Margins: 15.48%
- Return on Equity: 11.16%
- Return on Assets: 7.96%
Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 2.87%
- Quick Ratio: 2.70%
Misc:
Frequently Asked Questions for BAVARIAN NORDIC (OTCMKTS:BVNRY)
What is BAVARIAN NORDIC's stock symbol?
BAVARIAN NORDIC trades on the OTCMKTS under the ticker symbol "BVNRY."
How were BAVARIAN NORDIC's earnings last quarter?
BAVARIAN NORDIC (OTCMKTS:BVNRY) issued its quarterly earnings data on Friday, August, 25th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.14 by $0.07. The company had revenue of $58.68 million for the quarter, compared to the consensus estimate of $50.65 million. BAVARIAN NORDIC had a return on equity of 11.16% and a net margin of 15.48%. View BAVARIAN NORDIC's Earnings History.
When will BAVARIAN NORDIC make its next earnings announcement?
Who are some of BAVARIAN NORDIC's key competitors?
Some companies that are related to BAVARIAN NORDIC include Wright Medical Group N.V. (WMGI), Nevro Corp. (NVRO), The Medicines Company (MDCO), Allscripts Healthcare Solutions (MDRX), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Select Medical Holdings Corporation (SEM), Blueprint Medicines Corporation (BPMC), Advanced Accelerator Applications S.A. (AAAP), Amicus Therapeutics (FOLD), Halozyme Therapeutics (HALO), Ironwood Pharmaceuticals (IRWD), Sage Therapeutics (SAGE), Myriad Genetics (MYGN), LifePoint Health (LPNT), Loxo Oncology (LOXO), Haemonetics Corporation (HAE) and Intrexon Corporation (XON).
How do I buy BAVARIAN NORDIC stock?
Shares of BAVARIAN NORDIC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BAVARIAN NORDIC's stock price today?
One share of BAVARIAN NORDIC stock can currently be purchased for approximately $14.20.
MarketBeat Community Rating for BAVARIAN NORDIC (OTCMKTS BVNRY)MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for BAVARIAN NORDIC (OTCMKTS:BVNRY) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for BAVARIAN NORDIC (OTCMKTS:BVNRY)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 9/15/2017 | Maxim Group | Reiterated Rating | Buy -> Hold | |  |
| 10/19/2016 | Cowen and Company | Reiterated Rating | Buy | | |
| 9/19/2016 | Piper Jaffray Companies | Reiterated Rating | Buy | | |
(Data available from 9/25/2015 forward)
Earnings History for BAVARIAN NORDIC (OTCMKTS:BVNRY)Earnings History by Quarter for BAVARIAN NORDIC (OTCMKTS BVNRY)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | | | | | | | |
| 8/25/2017 | Q2 2017 | $0.14 | $0.07 | $50.65 million | $58.68 million | View | N/A | |
| 5/4/2017 | Q1 2017 | $0.04 | ($0.01) | $37.88 million | $28.33 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for BAVARIAN NORDIC (OTCMKTS:BVNRY)Current Year EPS Consensus Estimate: $2.17 EPS
Next Year EPS Consensus Estimate: $1.16 EPS
Dividend History for BAVARIAN NORDIC (OTCMKTS:BVNRY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for BAVARIAN NORDIC (OTCMKTS:BVNRY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for BAVARIAN NORDIC (OTCMKTS:BVNRY)
Latest Headlines for BAVARIAN NORDIC (OTCMKTS:BVNRY)
| Source: |
|
BAVARIAN NORDIC (BVNRY) Chart for Monday, September, 25, 2017
